Literature DB >> 15771597

Saturation with oxygen for ductal dependent congenital heart diseases before and after the prostaglandin therapy.

Senka Dinarević1, Hajrija Maksić, Majda Haznadar.   

Abstract

Ductal dependent congenital heart diseases represent 14-20% of all congenital heart diseases. A primary goal of the treatment of these diseases is to retain ductus open until the final cardiosurgical treatment. Prostaglandins are presently the only medicaments, which have a capability to keep ductus open. By means of a retrospective study in a period from January, 2000 until December, 2002 at the Paediatric clinic of the Clinical centre of the University in Sarajevo, 14 patients (treated with prostaglandins) diagnosed with ductal dependent congenital heart diseases were analyzed. In our sample, there are 9/14 male patients (64.3%), 11/14 (78.6%) were full-term newborns, while 10/14 (71.4%) were eutrophic at birth. An average saturation increase, after the prostaglandin therapy, measured in blood from the capillaries is 29, and measured transcutanlly is 32 units. Duration of prostaglandin therapy in our study was on average 17.2 days. The most common cause of death was insufficientia cardiorespiratoria (4 out of 11), but sepsis/infection (3 out of 11) and insufficientia renalis were also common. 78.6% (11 out of 14) patients died partly because of the complexity of these diseases, but also because a cardiosurgical treatment is delayed. A goal of this study is evaluation of saturation with oxygen before and after the prostaglandin therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15771597      PMCID: PMC7214061          DOI: 10.17305/bjbms.2005.3329

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  10 in total

1.  Neonatal transport issues with prostaglandin E1 infusions.

Authors:  Thomas C Grubbs; Nancy L Kraft
Journal:  Air Med J       Date:  2002 May-Jun

2.  Gastric-outlet obstruction induced by prostaglandin therapy in neonates.

Authors:  N Peled; O Dagan; P Babyn; M M Silver; G Barker; J Hellmann; D Scolnik; G Koren
Journal:  N Engl J Med       Date:  1992-08-20       Impact factor: 91.245

3.  Congenital heart disease in 56,109 births. Incidence and natural history.

Authors:  S C Mitchell; S B Korones; H W Berendes
Journal:  Circulation       Date:  1971-03       Impact factor: 29.690

4.  Prostaglandin E1 in infants with congenital heart disease: Indian experience.

Authors:  A Saxena; M Sharma; S S Kothari; R Juneja; S C Reddy; R Sharma; A Bhan; P Venugopal
Journal:  Indian Pediatr       Date:  1998-11       Impact factor: 1.411

5.  Trends and outcomes after prenatal diagnosis of congenital cardiac malformations by fetal echocardiography in a well defined birth population, Atlanta, Georgia, 1990-1994.

Authors:  E Montaña; M J Khoury; J D Cragan; S Sharma; P Dhar; D Fyfe
Journal:  J Am Coll Cardiol       Date:  1996-12       Impact factor: 24.094

6.  Cognitive function and age at repair of transposition of the great arteries in children.

Authors:  J W Newburger; A R Silbert; L P Buckley; D C Fyler
Journal:  N Engl J Med       Date:  1984-06-07       Impact factor: 91.245

7.  [Use of prostaglandins in neonatal cardiology].

Authors:  S Dinarević; S Kurtagić; H Maksić
Journal:  Med Arh       Date:  2000

8.  Neonatal urticaria due to prostaglandin E1.

Authors:  E L Carter; M C Garzon
Journal:  Pediatr Dermatol       Date:  2000 Jan-Feb       Impact factor: 1.588

9.  Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy.

Authors:  Aparna Joshi; Walter E Berdon; Adele Brudnicki; Gary LeQuesne; Carrie Ruzal-Shapiro; Constance Hayes
Journal:  Pediatr Radiol       Date:  2002-03-23

10.  Left ventricular function after repair of tetralogy of fallot and its relationship to age at surgery.

Authors:  K M Borow; L H Green; A R Castaneda; J F Keane
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.